Cargando…
Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study
BACKGROUND: Preterm birth complications are one of the leading causes of death among children under 5 years of age. Despite advances in medical care, many survivors face a lifetime of disability, including mental and physical retardation, and chronic lung disease. More recently, both allogenic and a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114055/ https://www.ncbi.nlm.nih.gov/pubmed/30186329 http://dx.doi.org/10.1155/2018/5268057 |
_version_ | 1783351125632614400 |
---|---|
author | Yang, Jie Ren, Zhuxiao Zhang, Chunyi Rao, Yunbei Zhong, Junjuan Wang, Zhu Liu, Zhipeng Wei, Wei Lu, Lijuang Wen, Jiying Liu, Guocheng Liu, Kaiyan Wang, Qi |
author_facet | Yang, Jie Ren, Zhuxiao Zhang, Chunyi Rao, Yunbei Zhong, Junjuan Wang, Zhu Liu, Zhipeng Wei, Wei Lu, Lijuang Wen, Jiying Liu, Guocheng Liu, Kaiyan Wang, Qi |
author_sort | Yang, Jie |
collection | PubMed |
description | BACKGROUND: Preterm birth complications are one of the leading causes of death among children under 5 years of age. Despite advances in medical care, many survivors face a lifetime of disability, including mental and physical retardation, and chronic lung disease. More recently, both allogenic and autogenic cord blood cells have been applied in the treatment of neonatal conditions such as hypoxic-ischemic encephalopathy (HIE) and bronchopulmonary dysplasia (BPD). OBJECTIVE: To assess the safety of autologous, volume- and red blood cell- (RBC-) reduced, noncryopreserved umbilical cord blood (UCB) cell infusion to preterm infants. METHOD: This study was a phase I, open-label, single-arm, single-center trial to evaluate the safety of autologous, volume- and RBC-reduced, noncryopreserved UCB cell (5 × 10(7)cells/kg) infusion for preterm infants <37 weeks gestational age. UCB cell characteristics, pre- and postinfusion vital signs, and laboratory investigations were recorded. Clinical data including mortality rates and preterm complications were recorded. RESULTS: After processing, (22.67 ± 4.05) ml UCB cells in volume, (2.67 ± 2.00) × 10(8) cells in number, with (22.67 ± 4.05) × 10(6) CD34+, (3.72 ± 3.25) × 10(5) colony forming cells (CFU-GM), and (99.7 ± 0.17%) vitality were infused to 15 preterm infants within 8 hours after birth. No adverse effects were noticed during treatment. All fifteen patients who received UCB infusion survived. The duration of hospitalization ranged from 4 to 65 (30 ± 23.6) days. Regarding preterm complications, no BPD, necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP) was observed. There were 1/15 (7%) infant with intraventricular hemorrhage (IVH), 5/15 (33.3%) infants with ventilation-associated pneumonia, and 10/15 (66.67%) with anemia, respectively. CONCLUSIONS: Collection, preparation, and infusion of fresh autologous UCB cells to preterm infants is feasible and safe. Adequately powered randomized controlled studies are needed. |
format | Online Article Text |
id | pubmed-6114055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-61140552018-09-05 Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study Yang, Jie Ren, Zhuxiao Zhang, Chunyi Rao, Yunbei Zhong, Junjuan Wang, Zhu Liu, Zhipeng Wei, Wei Lu, Lijuang Wen, Jiying Liu, Guocheng Liu, Kaiyan Wang, Qi Stem Cells Int Research Article BACKGROUND: Preterm birth complications are one of the leading causes of death among children under 5 years of age. Despite advances in medical care, many survivors face a lifetime of disability, including mental and physical retardation, and chronic lung disease. More recently, both allogenic and autogenic cord blood cells have been applied in the treatment of neonatal conditions such as hypoxic-ischemic encephalopathy (HIE) and bronchopulmonary dysplasia (BPD). OBJECTIVE: To assess the safety of autologous, volume- and red blood cell- (RBC-) reduced, noncryopreserved umbilical cord blood (UCB) cell infusion to preterm infants. METHOD: This study was a phase I, open-label, single-arm, single-center trial to evaluate the safety of autologous, volume- and RBC-reduced, noncryopreserved UCB cell (5 × 10(7)cells/kg) infusion for preterm infants <37 weeks gestational age. UCB cell characteristics, pre- and postinfusion vital signs, and laboratory investigations were recorded. Clinical data including mortality rates and preterm complications were recorded. RESULTS: After processing, (22.67 ± 4.05) ml UCB cells in volume, (2.67 ± 2.00) × 10(8) cells in number, with (22.67 ± 4.05) × 10(6) CD34+, (3.72 ± 3.25) × 10(5) colony forming cells (CFU-GM), and (99.7 ± 0.17%) vitality were infused to 15 preterm infants within 8 hours after birth. No adverse effects were noticed during treatment. All fifteen patients who received UCB infusion survived. The duration of hospitalization ranged from 4 to 65 (30 ± 23.6) days. Regarding preterm complications, no BPD, necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP) was observed. There were 1/15 (7%) infant with intraventricular hemorrhage (IVH), 5/15 (33.3%) infants with ventilation-associated pneumonia, and 10/15 (66.67%) with anemia, respectively. CONCLUSIONS: Collection, preparation, and infusion of fresh autologous UCB cells to preterm infants is feasible and safe. Adequately powered randomized controlled studies are needed. Hindawi 2018-08-15 /pmc/articles/PMC6114055/ /pubmed/30186329 http://dx.doi.org/10.1155/2018/5268057 Text en Copyright © 2018 Jie Yang et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Yang, Jie Ren, Zhuxiao Zhang, Chunyi Rao, Yunbei Zhong, Junjuan Wang, Zhu Liu, Zhipeng Wei, Wei Lu, Lijuang Wen, Jiying Liu, Guocheng Liu, Kaiyan Wang, Qi Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study |
title | Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study |
title_full | Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study |
title_fullStr | Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study |
title_full_unstemmed | Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study |
title_short | Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study |
title_sort | safety of autologous cord blood cells for preterms: a descriptive study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114055/ https://www.ncbi.nlm.nih.gov/pubmed/30186329 http://dx.doi.org/10.1155/2018/5268057 |
work_keys_str_mv | AT yangjie safetyofautologouscordbloodcellsforpretermsadescriptivestudy AT renzhuxiao safetyofautologouscordbloodcellsforpretermsadescriptivestudy AT zhangchunyi safetyofautologouscordbloodcellsforpretermsadescriptivestudy AT raoyunbei safetyofautologouscordbloodcellsforpretermsadescriptivestudy AT zhongjunjuan safetyofautologouscordbloodcellsforpretermsadescriptivestudy AT wangzhu safetyofautologouscordbloodcellsforpretermsadescriptivestudy AT liuzhipeng safetyofautologouscordbloodcellsforpretermsadescriptivestudy AT weiwei safetyofautologouscordbloodcellsforpretermsadescriptivestudy AT lulijuang safetyofautologouscordbloodcellsforpretermsadescriptivestudy AT wenjiying safetyofautologouscordbloodcellsforpretermsadescriptivestudy AT liuguocheng safetyofautologouscordbloodcellsforpretermsadescriptivestudy AT liukaiyan safetyofautologouscordbloodcellsforpretermsadescriptivestudy AT wangqi safetyofautologouscordbloodcellsforpretermsadescriptivestudy |